StockDrifts LogoStockDrifts

Prestige Biologics 334970

Company
프레스티지바이오로직스Prestige Biologics
Insiders
1
Buys
6
Total Value
₩7M ($5K)
Avg Return
+0.82%
Last Filing
2026-07-09

Prestige Biologics (334970) has 6 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩7M ($5K) in reported transaction value. The earliest filing StockDrifts holds for Prestige Biologics is dated 2024-03-29; the most recent is 2026-07-09. Across these filings the average return since disclosure is +0.82%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-07-09BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO3.6K₩1,830+0.8%₩7M ($5K)
2026-06-30BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO8.0K---
2026-06-29BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO16.2K---
2026-06-26BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO28.8K---
2026-06-25BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO22.0K---
2026-06-24BUYMarket Buy
김 마이클 진우
Kim Michael Jinwoo
CEO25.0K---
2025-05-29BUY주식매수선택권
동현철
Dong Hyeon-cheol
Other non-executive directors35.0K₩3,910-27.6%₩137M ($95K)
2024-09-25BUY유상신주취득
프레스티지바이오파마
Prestige Biopharma
-15.9M₩5,950-52.4%₩94.7B ($65.8M)
2024-03-29BUY주식매수선택권
동현철
Dong Hyeon-cheol
Other non-executive directors80.0K₩4,635-38.9%₩371M ($258K)
2024-03-29BUY주식매수선택권
양재영
Jaeyoung Yang
Managing Director22.5K₩4,635-38.9%₩104M ($72K)

Frequently asked questions

Who has been buying Prestige Biologics stock?
1 distinct insiders have filed 6 disclosed insider purchases in Prestige Biologics (334970), most recently on 2026-07-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Prestige Biologics have?
Prestige Biologics has 6 buy-side and 0 sell-side disclosures on record, covering ₩7M ($5K) in total reported value, spanning 2024-03-29 to 2026-07-09.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.